keyword
https://read.qxmd.com/read/38018328/excellent-hepatitis-c-virus-cure-rates-despite-increasing-complexity-of-people-who-use-drugs-integrated-test-stage-treat-study-final-outcomes
#1
JOURNAL ARTICLE
Margaret O'Sullivan, Anna-Marie Jones, Adele Mourad, Yazan Haddadin, Sumita Verma
Achieving hepatitic C virus (HCV) elimination requires linking people who use drugs (PWUD) into care. We report final direct-acting antivirals (DAAs)-based outcomes from the Integrated-Test-stage -Treat (ITTREAT) study. Project ITTREAT (2013-2021), based at an addiction centre, was a 'one-stop' service with innovative linkage to care strategies. Primary outcome was sustained virological response (SVR12) (intention to treat ITT) including whether individuals were recruited in first (period 1) versus last four (period 2 included the COVID-19 pandemic) years of the study...
November 28, 2023: Journal of Viral Hepatitis
https://read.qxmd.com/read/37484035/la-r%C3%A3-duction-du-risque-d-infection-p%C3%A3-rinatale-chez-les-nouveau-n%C3%A3-s-de-m%C3%A3-res-dont-les-soins-pr%C3%A3-natals-%C3%A3-taient-inappropri%C3%A3-s
#2
REVIEW
Ari Bitnun, Laura Sauvé, Sergio Fanella
Le risque que des infections maternelles ne soient ni décelées ni traitées augmente lorsque les soins prénatals sont inappropriés, ce qui met la santé de la mère et de son nouveau-né à risque. Lorsqu'une femme enceinte se présente tardivement pour recevoir des soins, les tests systématiques qui influent sur la prise en charge du nouveau-né devraient inclure l'antigène de surface de l'hépatite B (AgHBs), la sérologie du virus de l'hépatite C (VHC), du virus de l'immunodéficience humaine (VIH) et de la syphilis, de même que le dépistage de la Chlamydia trachomatis et de la Neisseria gonorrhoeae ...
August 2023: Paediatrics & Child Health
https://read.qxmd.com/read/37352795/-not-available
#3
JOURNAL ARTICLE
C Mattern, D Pourette, S F Andriamandimby, J Rabarison, A Darsot, B Ralaizara, M Vray, Y Shimakawa, T Giles-Vernick
OBJECTIVES: Madagascar faces many difficulties in accessing diagnosis and treatment of hepatitis B. The prevalence of chronic hepatitis B infection is estimated at 6.9%. The costs associated with screening and treatment are high and not easily accessible. This article proposes a reflection on the challenges and difficulties of access to diagnosis and treatment for patients with chronic hepatitis B. METHOD: The "Neo Vac" study aimed to document the life paths of people living with chronic hepatitis B, their difficulties and their perceptions of HBV...
June 21, 2023: Revue D'épidémiologie et de Santé Publique
https://read.qxmd.com/read/37067209/-evaluation-of-the-correlation-of-hcv-core-antigen-levels-with-hcv-rna-levels-in-the-diagnosis-and-treatment-follow-up-of-hepatitis-c-virus-infections
#4
JOURNAL ARTICLE
Türkan Erşen, Tercan Us, Müge Aslan, Ayşegül Özakyol, Tuncer Temel, Gül Durmaz
Hepatitis C virus (HCV) infections are an important public health issue across the world because of the high risk of chronicity potential, impossibility of protection by vaccination and serious complications such as hepatocellular carcinoma. The aim of this study was to evaluate the correlation of HCV core antigen test with HCV RNA in the diagnosis and treatment follow-up and to discuss the status of being an alternative test in routine use. In the first step of the study, the compatibility of the methods was investigated by applying the HCV core antigen test to 600 serum samples from patients with pre diagnosis of HCV infection for whom anti-HCV and HCV RNA tests were routinely studied in the molecular microbiology laboratory of medical microbiology department between December 2016 and December 2018...
April 2023: Mikrobiyoloji Bülteni
https://read.qxmd.com/read/36566134/-sotorasib-treatment-in-kras-g12c-mutated-non-small-cell-lung-cancer-experience-in-the-tours-university-hospital
#5
REVIEW
C Bessy, T Blin, E Pichon, S Marchand-Adam, D Carmier
Following the CodeBreak 100 study, since 2021 sotorasib has been available in France, with authorization for early access in treatment of non-small cell lung cancer with a KRAS G12C mutation. Our retrospective observational study was designed to determine the efficacy and safety of sotorasib under real-life conditions in patients treated at the Tours CHRU. Our study of 15 patients showed sotorasib to be effective in 47% of cases, with overall survival of 4 months and median progression-free survival of 5.5 months for responders...
December 22, 2022: Revue des Maladies Respiratoires
https://read.qxmd.com/read/36415562/research-trends-analysis-of-chronic-hepatitis-c-versus-nonalcoholic-fatty-liver-disease-a-literature-review-text-mining-analysis-of-publications
#6
JOURNAL ARTICLE
Eyal Klang, Shelly Soffer, Lee Alper, Orit Shimon, Yiftach Barash, Yana Davidov, Mariya Likhter, Oranit Cohen-Ezra, Gil Ben Yakov, Ziv Ben-Ari
BACKGROUND: Hepatits C virus (HCV) rates have lowered due to direct-acting antiviral treatment. Nonalcoholic steatohepatitis (NASH)/nonalcoholic fatty liver disease (NAFLD) is rising with no available therapy. We employed text-mining to analyze trends in HCV and NAFLD research from the past two decades. MATERIALS AND METHODS: We queried PubMed for all HCV and NASH/NAFLD entries published between 2000 and 2020. We compared the total number of publications on both etiologies...
November 2022: Health Science Reports
https://read.qxmd.com/read/36383852/experience-in-managing-action-research-on-hepatitis-c-survey-in-the-prison-community
#7
JOURNAL ARTICLE
Geisa Perez Medina Gomide, Mariana Dos Santos Teixeira, Guilherme Andrade Pereira, Fernanda Carolina Camargo, Beatriz Guerta Pastori, Felipe Ferreira Dias, Júlio Cesar do Carmo Ferreira, Nathan Castro Silva, Otilia Silva de Carvalho Neta, Pedro Teixeira Meireles, Vanessa Guizolfe Sales de Lima, Leonora De Zorzi Piccoli, Rejane Andrea de Paulo Cunha, Douglas Reis Abdalla, Cristina da Cunha Hueb Barata de Oliveira
We aimed to report the experience in managing action research on hepatitis C investigation in the prison community in the Triângulo Mineiro region, Minas Gerais, Brazil. The proposal was developed from March 2019 to March 2020, reaching 240 people to contain the spread of the disease through a survey, testing, and monitoring of positive cases. We adopted intersectoral action with articulation between Universities, Medical Society, Teaching Hospital, and State Secretariat for Justice and Public Security. Strategies for the management of action research are described: study settings and stakeholders, registration and formalization of the activity, application of tests, and management of reagent inmates...
December 2022: Ciência & Saúde Coletiva
https://read.qxmd.com/read/36066099/is-hepatitis-b-immunization-effective-during-chronic-liver-fibrosis-investigation-of-secretory-and-cellular-immune-responses-on-an-experimental-model
#8
JOURNAL ARTICLE
Başak Kayhan, Zeynal Mete Karaca, Esra Canpolat, Veysel Ersan, Mehmet Gül, Saim Yoloğolu, Sezai Yilmaz
Objective: Adults with end-stage of chronic liver diseases have lower antibody titers after Hepatits-B vaccination. We have less amount of knowlegdge about the effect of non-viral cause chronic liver fibrosis on vaccination. In this study we investigated the effect of non-viral chronic liver fibrosis on Hepatitis B vaccine and the effect of tetanous toxoid co-adminsitration at the level of humoral and cellular immune responses in an experimental model. Methods: Hepatitis B vaccine was administered either alone or in combination with tetanus toxoid in thioacetamide induced fibrotic BALB/c mice...
September 6, 2022: Immunopharmacology and Immunotoxicology
https://read.qxmd.com/read/35475818/factors-associated-with-hepatitis-c-treatment-adherence-an-integrative-review
#9
JOURNAL ARTICLE
Layla Tatiane Côco, Giovanni Faria Silva, Fernando Gomes Romeiro, Ana Teresa de Abreu Ramos Cerqueira
This integrative review examined factors associated with hepatitis C treatment adherence. The articles included were published in English, Spanish and Portuguese in the Lilacs, Medline, PsycINFO, Web of Science, Scopus and CINAHL databases, between 2000 and 2019. Initially, 540 publications were found and, after applying the study inclusion criteria, 22 articles were selected. Percentage non-adherence to treatment ranged from 12% to 32%. The variables identified as facilitating adherence were: receiving treatment for psychiatric disorders identified during treatment; knowing about medications and disease; receiving less complex treatment with greater likelihood of cure; fewer adverse events; social support; doctor-patient communication; and/or being in relationships...
April 2022: Ciência & Saúde Coletiva
https://read.qxmd.com/read/35120640/a-4-days-on-and-3-days-off-maintenance-treatment-strategy-for-adults-with-hiv-1-anrs-170-quatuor-a-randomised-open-label-multicentre-parallel-non-inferiority-trial
#10
RANDOMIZED CONTROLLED TRIAL
Roland Landman, Pierre de Truchis, Lambert Assoumou, Sidonie Lambert, Jonathan Bellet, Karine Amat, Bénédicte Lefebvre, Clotilde Allavena, Christine Katlama, Yazdan Yazdanpanah, Jean-Michel Molina, Ventzislava Petrov-Sanchez, Séverine Gibowski, Jean C Alvarez, Jacques Leibowitch, Jacqueline Capeau, Soraya Fellahi, Martin Duracinsky, Laurence Morand-Joubert, Dominique Costagliola, Jean-Claude Alvarez, Pierre-Marie Girard
BACKGROUND: Intermittent (on 4 days per week) antiretroviral therapy (ART) for patients with HIV-1 might be more convenient, better tolerated, and cheaper than continuous treatment. We aimed to establish the efficacy and safety of a 4-days-on and 3-days-off (intermittent) maintenance regimen versus a standard 7 day (continuous) maintenance regimen. METHODS: In a randomised, open-label, multicentre, parallel, non-inferiority trial, we randomly assigned (1:1) adults with HIV-1 infection with a plasma viral load (pVL) of less than 50 copies per mL for more than 12 months and no drug-resistance mutations to either the intermittent regimen or their existing continuous maintenance regimen, with stratification according to third therapeutic agent (protease inhibitor, non-nucleoside reverse transcriptase inhibitor, or integrase-strand transfer inhibitor)...
February 2022: Lancet HIV
https://read.qxmd.com/read/35088961/-investigation-of-hepatitis-c-virus-hcv-genotypes-by-reverse-hybridisation-strip-assay-and-dna-sequence-analysis-methods
#11
JOURNAL ARTICLE
Pelin Özmen, Selma Gökahmetoğlu
Hepatitis C Virus (HCV) is a virus that is estimated to infect approximately 185 million people worldwide and causes 350 000 deaths each year. The target in HCV treatment is the sustained virological response (SVR), and the most important virological factors determining SVR are genotype and baseline HCV-RNA levels. In this study, it was aimed to compare the HCV genotypes and subtypes detected by the "line probe assay (LIPA)" method with sequence analysis. HCV genotypes and subtypes were investigated by line probe assay (LIPA) (NLM analytica, Italy) and sequence analysis methods in 212 patients with chronic HCV diagnosis and with HCV RNA viral load of 10⁴ IU/ml and above...
January 2022: Mikrobiyoloji Bülteni
https://read.qxmd.com/read/34799189/-delta-hepatitis-epidemiology-diagnostic-natural-history-and-treatment
#12
JOURNAL ARTICLE
D Loureiro, C Castelnau, C M Bed, T Asselah
Hepatitis B virus is a small enveloped RNA virus, which replicates independently but requires the hepatitis B virus (HBV) to provide the envelope proteins necessary for the assembly of its own viral particles. Approximately 5% of chronic hepatitis B virus carriers are infected with HDV. HBV vaccination remains the best preventive treatment for HDV. All HBV patients should be screened for HDV (anti-HDV serology). In case of positive HDV serology, HDV replication (HDV RNA) should be investigated using a sensitive and specific technique...
November 16, 2021: La Revue de Médecine Interne
https://read.qxmd.com/read/34759100/-hepatits-b-virus-reactivation-in-patients-receiving-immunosuppressive-therapy-or-chemotherapy-and-effective-prophylactic-management-a-prospective-observational-study-in-a-hospital-over-an-8-year-period
#13
JOURNAL ARTICLE
Kazuo Notsumata, Hiroki Matsukawa, Genta Yamakawa, Yoshimoto Nomura, Katsuyoshi Nomura, Teruyuki Ueda, Taku Sanada, Hiroyuki Watanabe, Daishu Toya
We investigated the development of hepatits B virus (HBV) reactivation in patients receiving immunosuppressive therapy or chemotherapy at our hospital for 8 years. Using the automatic checking system for HBV reactivation coded using medical information that has been in operation in our hospital since October 2012, we prospectively observed the occurrence status of HBV reactivation in immunosuppressive/chemotherapy cases for 8 years. HBV reactivation occurred in 31 of 1516 patients with HBV infection. It occurred annually between 1 and 7 cases in multiple clinical departments, and in 8 of 59 patients treated with rituximab, 10 of 653 patients treated with antineoplastic agents, 10 of 399 patients treated with steroids, and 3 of 212 patients treated with direct-acting antivirals...
2021: Nihon Shokakibyo Gakkai Zasshi, the Japanese Journal of Gastro-enterology
https://read.qxmd.com/read/34733398/-seroprevalence-of-hepatitis-c-virus-hcv-antibodies-and-associated-factors-based-on-voluntary-screening-data-collection-in-the-general-population-in-benin-in-2016
#14
JOURNAL ARTICLE
Aboudou Raïmi Kpossou, Benoît Kouwakanou, Comlan N Déhougbèa Martin Sokpon, Khadidjatou Saké Alassane, Marc Moboladji Bankolé, Carin Ahouada, Rodolph Koffi Vignon, Vincent Zoundjiekpon, Fadel Sourokou, Jean Séhonou, Nicolas Kodjoh
Introduction: hepatitis C is a public health problem worldwide, in particular in sub-Saharan Africa. The purpose of this study is to determine the seroprevalence of hepatitis C virus antibodies and associated factors during a voluntary general population screening program in Benin. Method: we conducted a descriptive and analytical cross-sectional study in 4 big cities of 4 different departments in Benin in July 2016. All volunteers of all ages, residing in these targeted cities, who gave their informed consent were included in the study...
2021: Pan African Medical Journal
https://read.qxmd.com/read/34539763/-epidemiology-of-hepatitis-c-virus-infection-in-colombiaepidemiologia-da-infec%C3%A3-%C3%A3-o-pelo-v%C3%A3-rus-da-hepatite-c-na-col%C3%A3-mbia
#15
JOURNAL ARTICLE
María C López-Osorio, Mauricio Beltrán, María-Cristina Navas
OBJECTIVE: To describe the epidemiology of hepatitis C virus (HCV) infection in Colombia. METHODS: Critical review of epidemiological studies of HCV infection in Colombia. The PubMed, SciELO, and ScienceDirect databases were searched for original articles and reviews on the subject published from 1989 to 2020. Reports from the National Institute of Health and the High Cost Account of the Ministry of Health and Social Protection were also reviewed. RESULTS: Data on seroprevalence of HCV antibodies in blood donors range from 1...
2021: Pan American Journal of Public Health
https://read.qxmd.com/read/34416803/-investigation-of-the-relationship-between-il28b-polymorphisms-and-plasma-il28b-levels-in-patients-with-chronic-hepatitis-b-or-c
#16
JOURNAL ARTICLE
Zeynep Koç Kuralay, Esra Tuğ, Işıl Fidan
Some single nucleotide polymorphisms (SNPs) of the gene encoding interleukin 28B (IL28B) may increase susceptibility to infection and chronicity in humans with hepatitis B and C viruses. In our study, we aimed to investigate the prevalence of rs12979860, rs8099917 and rs12980275 SNPs in IL28B in patients with hepatitis B (HBV) or hepatitis C Virus (HCV) infection and to determine the relationship of these polymorphisms with plasma IL28B levels. For this purpose, 64 HBV-infected and 66 HCV-infected patients and 70 healthy individuals were included in the study...
July 2021: Mikrobiyoloji Bülteni
https://read.qxmd.com/read/34221451/molecular-detection-and-genomic-characterization-of-diverse-hepaciviruses-in-african-rodents
#17
JOURNAL ARTICLE
Magda Bletsa, Bram Vrancken, Sophie Gryseels, Ine Boonen, Antonios Fikatas, Yiqiao Li, Anne Laudisoit, Sebastian Lequime, Josef Bryja, Rhodes Makundi, Yonas Meheretu, Benjamin Dudu Akaibe, Sylvestre Gambalemoke Mbalitini, Frederik Van de Perre, Natalie Van Houtte, Jana Těšíková, Elke Wollants, Marc Van Ranst, Oliver G Pybus, Jan Felix Drexler, Erik Verheyen, Herwig Leirs, Joelle Gouy de Bellocq, Philippe Lemey
Hepatitis C virus (HCV; genus Hepacivirus ) represents a major public health problem, infecting about three per cent of the human population. Because no animal reservoir carrying closely related hepaciviruses has been identified, the zoonotic origins of HCV still remain unresolved. Motivated by recent findings of divergent hepaciviruses in rodents and a plausible African origin of HCV genotypes, we have screened a large collection of small mammals samples from seven sub-Saharan African countries. Out of 4,303 samples screened, eighty were found positive for the presence of hepaciviruses in twenty-nine different host species...
January 2021: Virus Evolution
https://read.qxmd.com/read/33949963/promoting-hiv-hepatitis-b-virus-and-hepatitis-c-virus-screening-among-migrants-with-a-language-barrier-protocol-for-the-development-and-evaluation-of-an-electronic-app-apid%C3%A3
#18
JOURNAL ARTICLE
Frédérique Thonon, Saleh Fahmi, Olivia Rousset-Torrente, Pascal Bessonneau, James W Griffith, Carter Brown, Olivier Chassany, Martin Duracinsky
BACKGROUND: Late diagnoses of HIV, hepatitis B, and hepatitis C are important public health problems that affect the population at large and migrants in particular. Missed opportunities of HIV and hepatitis screening are numerous, with language differences being a significant barrier to testing. Several studies have shown that migrants who do not speak the language of the health provider are less likely to get tested, due to health providers' reluctance to offer a test and to migrants' reluctance to accept testing...
May 5, 2021: JMIR Research Protocols
https://read.qxmd.com/read/33737346/extending-the-conversation-over-the-immune-related-hepatotoxicity-author-response-to-dr-gauci-et-al
#19
COMMENT
Dimitrios C Ziogas, Helen Gogas
Immune-related hepatotoxicity (IRH) remains the subject of many immune-oncology debates due to its challenging diagnosis and management. Although it is currently defined by the restrictive Common Terminology Criteria for Adverse Events (CTCAE), the term of IRH covers a wide range of liver pathologies, including hepatitic, cholangitic, mixed, steatotic and nonspecific patterns of injury. Even when liver biopsy is performed, the recognized histopathological findings cannot predict the response to steroids or the need for secondary immunosuppression, and usually do not significantly modify the suggested empirical treatment of IRH...
March 2021: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/33729415/-brazilian-protocol-for-sexually-transmitted-infections-2020-viral-hepatitis
#20
JOURNAL ARTICLE
Geraldo Duarte, Paula Pezzuto, Tiago Dahrug Barros, Gláucio Mosimann Junior, Flor Ernestina Martínez-Espinosa
This article discusses viral hepatitis, a theme addressed by the Clinical Protocol and Therapeutic Guidelines to Comprehensive Care for People with Sexually Transmitted Infections and, more precisely, by the Clinical Protocols and Therapeutic Guidelines for Hepatitis B and Hepatitis C and Coinfections, published by the Brazilian Ministry of Health. Besides the broad spectrum of health impairment, hepatitis A, B and C viruses also present different forms of transmission, whether parenteral, sexual, vertical or oral...
2021: Epidemiologia e Servicos de Saude: Revista do Sistema Unico de Saude do Brasil
keyword
keyword
170952
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.